Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 8
Submit an article Journal homepage
61
Views
22
CrossRef citations to date
0
Altmetric
Review

Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy

A Razzaque Ahmed Harvard School of Dental Medicine, Department of Oral Medicine and Infection and Immunity, 188 Longwood Avenue, Boston, MA 02115, USA. [email protected]
Pages 1019-1032 | Published online: 24 Feb 2005

Bibliography

  • NOUSARI HC, ANHALT GJ: Pemphigusand bullous pemphigoid. Lancet (1999) 354:667–672.
  • SCOTT JE, AHMED AR: The blisteringdiseases. Med. Clin. North Am. (1998) 82:1239–1283.
  • KORMAN N: Pemphigus. J. Am. Acad. Dermatol (1988) 18:1219–1238.
  • PALESTINE RE KOSSARD S, DICKEN CH: Epidermolysis bullosa acquisita: a heterogeneous disease. j. Am. Acad. Dermatol (1981) 5:43–53.
  • YANCEY KB, EGAN CA: Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA (2000) 284:350–356
  • AHMED AR, KURGIS BS, ROGERS RS: Cicatricial Pemphigoid.j. Am. Acad. Dermatol (1991) 24:987–1001.
  • 10TH GG, JONKMAN MF: Therapy of pemphigus. Clin. Demerol (2001) 19:761–767
  • DUTZ JP, HO VC: Immunosuppressive agents in dermatology. An update. Dermatol Clin. (1998) 16:235–251.
  • KHUMALO NP, MURRELL DF, WOJNAROWSKA F, KIRTSCHIG G: A systematic review of treatments for bullous pemphigoid. Arch. Dermatol (2002) 138:385–389
  • KIRTSCHIG G, MURRELL D, WOJNAROWSKA F, KHUMALO N: Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and Epidermolysis Bullosa Acquisita: a systematic literature review. Arch. Dermatol (2002) 138:380–384.
  • •A good review of MMP and EBA with an English perspective.
  • ENGINEER L, AHMED AR: Emerging treatment for epidermolysis bullosa acquisita. jAm. Acad. Dermatol (2001) 44:818–828.
  • •Good coverage of options for treating EBA, including IVIg.
  • DAHL MV, BRIDGES AG: Intravenous globulin: fighting antibodies with antibodies. Am. Acad. Dermatol (2001) 45:775–783.
  • •An interesting editorial that carefully examines the use of IVIg therapy.
  • TAPPEINER G, STEINER A: High-dosage intravenous immunoglobulin: therapeutic failure in pemphigus and pemphigoid. Am. Acad. Dermatol (1989) 20:684–685.
  • HUMBERT P, DERANCOURT C, AUBIN F, AGACHE P: Effects of intravenous gamma globulin in pemphigus. j Am. Acad. Dermatol (1990) 22:326.
  • MESSER G, SIZMANN N, FEUCHT H, MEURER M: High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br. Dermatol (1995) 133:1014–1015.
  • BECKERS RCY, BRAND A, BJ, BOOM BW: Adjuvant high-dose intravenous immunoglobulins in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br. Dermatol (1995) 133:289–293.
  • BEWELY AP, KEEFE M: Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br. J. Dermatol (1996) 135:128–129.
  • WEVER S, ZILLIKENS D, EB: Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy Br. J. Dermatol 135:852–856.
  • COLONNA L, CIANCHINI F, FREZZOLINI A, DE PITA 0, LELLA G, PUDDU P: Intravenous immunoglobulins for pemphigus vulgaris: adjuvant vs first choice therapy. Br. Dermatol (1998) 138:1102–03.
  • HARMAN KE, BLACK MM: High-dose intravenous immunoglobulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br. Dermatol (1999) 140:865–874.
  • JOLLES S, HUGES J, RUSTIN M: Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris. Am. Acad. Dermatol (1999) 40:499–500.
  • AHMED AR: Intravenous therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. (2001) 45:679–690.
  • ••A comprehensive, detailed report on use ofIVIg in PV.
  • SAMI N, QURESHI A, RUOCCO E, AHMED AR: Corticosteroid-Sparing effect of intravenous immunoglobulin therapy in with pemphigus vulgaris. Arch. Dermatol (2002) 138:1158–1162.
  • SAMI N, BHOL K, AHMED AR: Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up, and treatment responses. Clin. Exp. Immunol (2001) 125:492–498.
  • AHMED AR, SAMI N: Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. Am. Acad. Dermatol (2002) 46:42–49.
  • ••The value of this publication lies in itrecognising that PF is not always a mild disease.
  • SAMI N, QURESHI A, AHMED AR: Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eurj Dermatol (2002) 12:174–178.
  • 10TH GG, JONKMAN MF: Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins. Br. J. Dermatol (1999) 141:583–585.
  • GODARD W, ROUJEAU JC, GUILLOT B, ANDRE C, RIFLE G: Bullous pemphigoid and intravenous gammaglobulin. Ann. Intern. Med. (1985) 103:964–965.
  • AHMED AR: Intravenous therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. Am. Acad. Dermatol (2001) 45:825–835.
  • ••The only detailed study of the use of IVIgin BE
  • FOSTER CS, AHMED AR: Intravenous therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology (1999) 106:2136–2143.
  • •The earliest report that documents that IVIg can prevent blindness.
  • URCELAY ML, McQUEEN A, DOUGLAS WS: Cicatricial pemphigoid treated with intravenous immunoglobulin. Br. Dermatol (1997) 137:477–478.
  • AHMED AR, COLON JE: Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid. Arch. Dermatol (2001) 137:1181–1189.
  • SAMI N, BHOL KC, AHMED AR: Intravenous immunoglobulin therapy in with multiple mucosal involvement in mucous membrane pemphigoid. Clio. Immunol (2002) 102:59-67. demonstrates that the process of fibrosis can be arrested.
  • LEVERKUS M, GEORGI M, NIE Z, HASHIMOTO T, BROCKER EB, ZILLKENS D: Cicatricial pemphigoid with circulation IgA and IgG autoantibodies to the central portion of the BP 180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. Am. Acad. Dermatol (2002) 46:116–122.
  • SAMI N, BHOL KC, AHMED AR: Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy long-term follow-up: influence of treatment on autoantibody titers to human alpha 6 integrin. Clio. Exp. Immunol (2002) 129:533–540.
  • MEIER F, SONNICHSEN K,-LEVER G, DOPFER R, RASSNER G: Epidermolysis bullosa acquisita: efficacy of high dose intravenous immunoglobulins. J. Am. Acad. Dermatol (1993) 29:334–337.
  • CALDWELL JB, YANCEY KB, RJM, JAMES WD: Bullosa Acquisita: efficacy of high dose intravenous immunoglobulins.. Am. Acad. Dermatol (1994) 31:827–828.
  • MOHR C, SUNDERKOTTER C, HILDEBRAN A, BIEL K, RUTTER A, RUTTER GH et al.: Successful treatment of Epidermolysis Bullosa Acquisita using intravenous immunoglobulins. Br. J. Dermatol (1995) 132:824–826
  • KOFLER H, WAMBACHER-GASSER B, TOPAR G, WEINLICH G, SCHULER G, HINTER Het al.: Intravenous immunoglobulin treatment in therapy-resistant Epidermolysis Bullosa Acquisita. J. Am. Acad. Dermatol (1997) 36:331–335
  • HARMAN KE, WHITTAM LR, WAKELING SH, BLACK MM: Severe refractory epidermolysis bullosa complicated by an esophageal stricture responding to intravenous immune globulin. ELI-. Dermatol (1987) 139:1126–1127.
  • JAPPE U, ZILLIKENS D, B, GOLLNICK H: epidermolysis bullosa Acquisita with ultraviolet radiation sensitivity. Br. J. Dermatol (2000) 142:517–520.
  • GOURGIOTOU K, EXADAKTYLOU D, ARONI K, RALLIS E, NICOLAIDOU E, H, KATSAMBAS AD: Epidermolysis Bullosa Acquisita: treatment with intravenous immunoglobulins. j. Euc Acad. Dermatol Venereol (2002) 16:77–80.
  • ENGINEER L, AHMED AR: Epidermolysis bullosa acquisita and multiple myeloma..1. Am. Acad. Dermatol (2002) 47:943–946
  • KHAN IU, BHOL KC, AR,:Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. I Am. Acad. Dermatol (1999) 40:485–488.
  • •Useful only because LABD is very rare.
  • KROISS M, VOGT T, M, STOLZ W: High-dose intravenous immunoglobulin is also effective in linear IgA disease. Br. Dermatol (2000) 142:582.
  • LETKO E, BHOL K, FOSTER CS, AHMED AR: Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmol (2000) 1078:1524–1528
  • HERN S, HARMAN K, BHOGAL BS, BLACK MM: A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporine. Clio. Exp. Dermatol (1998) 3:185–188.
  • TEHRANCHI-NIA Z, QURESHI TA, AHMED AR: Pemphigus vulgaris in older adults. J. Am. Geriam. Soc. (1998) 461:92–94
  • MUTASIM DF, ANHALT GJ: Bullous diseases in the elderly. Clio. Geriatr. Med. (2002) 18:43–58.
  • JUN H, ANTAYA RJ: Pemphigus vulgaris in an adolescent. Cum Opin. Pediam (2002) 14:426–428
  • METRY DW, HEBERT AA, RE: Nonendemic pemphigus foliaceus in children. J. Am. Acad. Dermatol (2002) 46:419–422.
  • JONES SK, SCHWAB HP, NORRIS DA: Childhood pemphigus foliaceus: case report and review of the literature. Pediam Dermatol (1986) 3:459–463.
  • SIMON DG, KRUTCHKOFF D, KASLOW RA, ZARBO R: Pemphigus in Hartford County, CT, from 1972 to 1977. Arch. Dermatol (1980) 1169:1035–1037
  • PISANT S, SHARAV Y, KAUFMAN E, POSNER LN: Pemphigus vulgaris: incidence in Jews of different ethnic groups, to age, sex, and initial lesion. Oral Surg. Oral Med. Oral Pathol (1974) 38:382–387.
  • KYRIAKIS K, TOSCA, LEHOUS Jet al: A five year retrospective study on pemphigus and pemphigoid. Australas. Dermatol (1989) 30:33–36.
  • HIETANEN J, SALO OP: Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Berm. Venereol (1982) 62(6):491–496
  • GOON AT, TAN SH: Comparative study of Pemphigus Vulgaris and Pemphigus Foliaceus in Singapore. Australas.j. Dermatol (2001) 42:172–175.
  • BASTUJI-GARIN S, SOUISSI R, L et al.: Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. j. Invest. Dermatol (1995) 104:302–305
  • DIAZ LA, SAMPAIO SA, RIVITTI EA, MARTINS CR, CUNHA PR, LOMBARDI C et al.: Endemic pemphigus foliaceus (Fogo Selvagem): II. Current and historic epidemiologic studies. j. Invest. Dermatol (1989) 92:4–12.
  • SAMPIO SA, RIVITTI EA, AOKI V, DIAZ LA: Brazilian pemphigus foliaceus, endemic pemphigus foliaceus, or fogo selvagem (wildfire). Dermatol Clio. (1994) 12:765–776.
  • HERNANDEZ-PEREZ E: Pemphigus inEl Salvador. An eight-year study (1970–1977). Int. J. Dermatol (1979) 18:645–648.
  • ZILLIKENS D, WEVER S, HASHIMOTO T, BROCKER EB: Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch. Dermatol (1995) 131:957–958.
  • BERNARD PP, VAILLANT L, LABEILLE B et al.: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch. Dermatol (1995) 131:48–52.
  • CHAN LS, AHMED AR, ANHALT GJ, BERNAUER W, COOPER KD, MJ et al.: The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch. Dermatol (2002) 138:370–379
  • FLEMING TE, KORMAN NJ: Cicatricial. J. Am. Acad. Dermatol (2000) 43:571–591.
  • NGUYEN QD, FOSTER CS: Cicatricial pemphigoid: diagnosis and treatment. mt. Ophthalmol Clin. (1996) 36:41–60.
  • WEINMAN D, STEWART MI, WOODLEY DT, GARCIA G: Epidermolysis bullosa acquisita (EBA) and esophageal webs: a new association. Am. J. Castroenterol (1991) 86:1518–1522.
  • CALLOT-MELLOT C, BODEMER C, CAUX F, BOURGAULT-VILLADA I, FRAITAG G, GOUDIE Get al: Epidermolysis bullosa acquisita in childhood. Arch. Dermatol (1997) 133:1122–1126
  • MEURER M, MILLNS JL, ROGERS RS III, JORDON RE: Oral Pemphigus Vulgaris: A report of ten cases. Arch. Dermatol (1977) 113:1520–1524.
  • BEUTNER EH, LEVER WF, WIEBSKY E, JORDON R, CHERTOCK B: Autoantibodies in pemphigus vulgaris.. Am. Acad. Dermatol (1965) 8:682–688.
  • BEUTNER EH, RHODES EL, HOLBOROW EJ: Autoimmunity in chronic bullous skin diseases. Immunofluorescent demonstration of three types of antibodies to skin in sera of patients with pemphigus, bullous pemphigoid and in other human sera. Clin. Exp. Immunol (1967) 2:141–151.
  • GRANDO SA: Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatol (2000) 201:290–295.
  • WEISSMAN V, FEUERMAN EJ, JOSHUA H, HAZAZ B: The correlation between the antibody titers in sera of patients with Pemphigus vulgaris and their clinical state. Inv. Dermatol (1978) 71:107–109
  • AMAGAI M: Autoimmunity against desmosomal cadherins in pemphigus. Dermatol Sci. (1999) 20:92–102.
  • AMAGAI M, KOMAI A, T, SHIRAKATA Y, HASHIMOTO K, YAMADA Tet al: Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br. J. Dermatol (1999) 140:351–357
  • •Describes the benefit of the ELISA for PV.
  • HASHIMOTO T, AMAGAI M, GARROD DR, NISHIKAWA T: and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1. Epithelial Cell Biol. (1995) 4:63–69
  • PERSON JR, ROGERS RS III: Bullous and cicatricial pemphigoid: clinical, histopathologic, and immunopathologic correlations. Mayo Clin. Proc. (1977) 52:54–56.
  • ASBRINK E, HOVMARK A: Clinical variations in bullous pemphigoid with respect to early symptoms. Acta Berm. Venereol (1981) 61:417–21.
  • YUNG CW, SOLTANI K, LORINCZ AL: Pemphigoid nodularis. I Am. Acad. Dermatol (1981) 5:54–60.
  • JORDAN RE, BEUTNER EH, WITEBSKY E, BLUMENTHAL G, HALE WL, LEVER WF: Basement zone antibodies in bullous pemphigoid. JAMA (1967) 200:751–756
  • BEUTNER EH, JORDAN RE, AND CHORZAELSKI TP: The immunopathology of pemphigus and bullous pemphigoid. Inv. Dermatol (1968) 51:63–68.
  • GAMMON WR, BRIGGAMAN RA, INMAN AO III, QUEEN LL, WHEELER: Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluor-escence on 1.0 M sodium chloride-separated skin. J. Inv. Dermatol (1985) 82:139–44.
  • GHOESTANI RF, NICOLAS JF, ROUSSELLE P, CLAUDY AL: Diagnostic value of indirect immuno- fluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch. Dermatol (1997) 133:1102–1107
  • STANLEY JR., TANAKA T, MUELLER S,KLAUS-KOVTUN V, ROOP D: Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. Clin. Invest. (1988) 82:1864–1870.
  • GREKIN PM, LEVY GN, KING AJ, DIAZ LA: Some biochemical properties of pemphigoid antigen bound to the surface of dissociated epidermal basal cells. J. Inv Dermatol (1981) 76:190–192
  • SCHMIDT E, OBE K, BROCKER EB, ZILLIKENS D: Serum levels of autoantibodies to BP 180 correlate with disease activity in patients with bullous. Arch. Dermatol (2000) 136:174–178.
  • AMO Y, OHKAWA T, TATSUTA M, HARNADA Y, FUJIMURA T, KATSUOKA K, HASHIMOTO T: Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. Sci. (2001) 26:14–18
  • •Describes the benefit of the ELISA for BE
  • AHMED AR, HOMBAL SM: Cicatricial pemphigoid. hat. J. Dermatol (1986) 25:90–96.
  • HANSON RD, OLSEN KD, ROGERS RS III: Upper aerodigestive tract manifestations of cicatricial pemphigoid. ann. Otol. Rhino]. Laryngol (1988) 97:493–499.
  • FOSTER CS: Cicatricial pemphigoid. Trans. Am. Ophthalmol (1986) 84:627–663.
  • SHKLAR G, McCARTHY PL: Oral lesions of mucous membrane pemphigoid. Arch Otolaryngol (1971) 93:354–364.
  • ROGERS RS III, SHERIDAN PJ, NIGHTINGALE SH: Desquammative gingivitis: clinical, histopathologic, and therapeutic observations.j Am. Acad. Dermatol (1982) 7:729–735.
  • BEAN SF, WAISMAN M, MICHEL B, THOMAS CL, KNOX JM, LEVINE M: Cicatricial pemphigoid: immunofluorescent studies. Arch. Dermatol (1972) 106:195–199.
  • ROGERS RS, PERRY HO, BEAN SF, JORDON RE: Immunopathology of cicatricial pemphigoid: studies of complement deposition. J. Invest. Dermatol (1977) 68:39–43.
  • DANTZIG P: Circulating antibodies in cicatricial pemphigoid. Arch Dermatol (1973) 108:264–266.
  • KORMAN NJ, WATSON RN: Immune-mediated subepithelial blistering diseases of the mucous membranes: Improving the detection of circulating autoantibodies by the use of concentrated sera. Arch. Dermatol (1996) 132:1194–1198.
  • KELLY SE, WOJNAROWSKA F: The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br. j Dermatol (1988) 118:31–40.
  • DOMLOGE-HULTSCH N, ANHALT GJ, GAMMON WR, LAZAROVA Z, BRIGGAMAN R, WELCH Metal.: Antiepiligrin cicatricial a subepithelial bullous disorder. Arch. Dermatol (1994) 130:1521–1529
  • BERNARD PB, PROST C, N, BASSET-SEGUIN N, DIDIERJEAN L, SAURAT J-H: The major cicatricial pemphigoid antigen is a 180 kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. I Inv. Dermatol (1992) 99:174–179.
  • BHOL KC, GOSS L, KUMARI S, COLON JE, AHMED AR: Autoantibodies to human alpha 6 integrin in patients with oral pemphigoid. Dent. Res. (2000) 80:1711–1715.
  • GAMMON WR, BRIGGAMAN RA, WOODLEY DT, HEALD PW, WHEELER CE JR: Epidermolysis bullosa acquisita-a pemphigoid-like disease. Am. Acad. Dermatol (1984) 11:820–832.
  • GAMMON WR: Epidermolysis bullosa acquisita. Semin. Dermatol (1988) 7:218–224.
  • GAMMON WR, BRIGGAMAN RA, INMAN AO, QUEEN LL, CE: Differentiating anti-lamina lucida and antisublamina densa anti-BMZ antibodies by indirect immuno fluorescence on 1.0 M sodium chloride-separated skin. J. Inv. Dermatol (1984) 82:139–144.
  • WOODLEY DT, BRIGGAMAN RA, O'KEEFE EJ, INMAN AO, QUEEN LL, GAMMON WR: Identification of the skin basement membrane autoantigen in Epidermolysis Bullosa Acquisita. N Eng.' Med. (1984) 310:1007–1013.
  • KORIVIAN NJ: New immunomodulating drugs in autoimmune blistering diseases. Dermatol Clio. (2001) 19:637–648.
  • WOJNAROWSKA F, KITSCHIG G, HIGHET AS, VENNING VA, KHUMALO NP: Guidelines for the management of bullous pemphigoid. Br. Dermatol (2002) 147:214–221.
  • ••A British perspective on managing BE
  • KRAIN LS, LANDAU JW, VD: Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch. Dermatol (1972) 106:657–661.
  • CHAFFINS ML, COLLISON D, FIVENSON DP: Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am. Acad. Dermatol. (1993) 28:998–1000.
  • PIAMPHONGSANT T: Pemphigus controlled by Dapsone. Br. Dermatol (1976) 94:681–686.
  • EBRINGER A, MacKAY IR: Pemphigus vulgaris successfully treated with cyclophosphamide. Ann. Intern. Med. (1969) 71:125–127.
  • LAPIDOTH M, DAVID M, BEN-AMITAI D, KATZENELSON V, LUSTIG S, SANDBANK M: The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. .1. Am. Acad. Dermatol (1994) 30:752–757.
  • WERTH VP: Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch. Dermatol (1996) 132:1435–1439.
  • PANDYA AG, SONTHEIMER RD: Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch. Dermatol (1992) 128:1626–1630.
  • ROOK AH, HEALD PW, NAHASIS GT et al.: Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris-preliminary report. Yale. Med. (1989) 62:647–652.
  • FINE JD, APPELL ML, GREEN LK, SAMS WM JR: Pemphigus vulgaris: combined treatment with intravenous corticocosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol (1988) 124:236–239.
  • 10TH GG, VAN DER MEER JB, JONKMAN MF: Dexamethasone pulse therapy in pemphigus. I Eur: Acad. Dermatol Venereol (2002) 16:607–611.
  • PIAMPHONGSANT T, S: Bullous pemphigoid controlled by dapsone. Dermatologica. (1976) 152:352–357.
  • PERSON JR, ROGERS RS III: Bullous pemphigoid responding to sulfapyridine and the fulfones. Arch. Dermatol (1977) 113:610–615.
  • BERK MA, LORINCZ AL: The treatment of bullous pemphigoid with tetracycline and niacinamide: a preliminary report. Arch. Dermatol (1986) 122:670–674.
  • MILLIGAN A, HUTCHINSON PE: The use of chlorambucil in the treatment of bullous pemphigoid. .1 Am. Acad. Dermatol (1990) 22:796–801.
  • BOHM M, BEISSERT S, SCHWARZ T, METZE D, LUGER T: Bullous treated with mycophenolate mofetil. Lancet. (1997) 349:541.
  • DAWE RS, NAIDOO DK, J: Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br. Dermatol (1997) 137:826–827.
  • ITOH T, HOSOKAWA H, SHIRAI Y, HORIO T: Successful treatment of bullous pemphigoid with pulse intravenous cyclophosphamide. Br. J. Dermatol (1996) 134:931–933.
  • SIEGEL J, EAGLSTEIN WH: High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch. Dermatol (1984) 120:1157–1165.
  • GOLDBERG NS, ROBINSON JK, ROENIGK HH JR, MARDER R, ROTHE M: Plasmapheresis therapy for bullous pemphigoid. Arch. Dermatol (1985) 121:1484–1485.
  • CHAN LS, AHMED AR, ANHALT GJ et al.: The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch. Dermatol (2002) 138:370–379.
  • ROGERS RS III, MEHREGAN DA: Dapsone therapy of cicatricial pemphigoid. Semin. Dermatol (1988) 7:201–205.
  • MISEROCCHI E, BALTATZIS S, ROQUE MR, AHMED AR, FOSTER CS: The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology (2002) 109:111–118.
  • WILLIAMS LC, NESBITT LT: Update on systemic glucocorticosteroids in dermatology. Dermatol Clio. (2001) 19:63–77.
  • OTLEY CC: Immunosuppression and skin cancer: pathogenic insights, therapeutic challenges, and opportunities of innovation. Arch. Dermatol (2002) 138:827–828.
  • HERBST A, BYSTRYN JC: Patterns of remission in PV. I Am. Acad. Dermatol (2000) 42:422–427.
  • AHMED AR, MOY R: Death in pemphigus. I Am. Acad. Dermatol (1982) 7:221–228.
  • SAVIN JA: The events leading to the death of patients with pemphigus and pemphigoid. Br. I Dermatol (1979) 1010:521–534.
  • NOUSARI HC, MORESI M, M, ANHALT GJ: Nonendemic foliaceus presenting as fatal bullous exfoliative erythroderma. Cutts. (2001) 67:251–252.
  • VENNING VA, WOJNAROWSKA F: Lack of predictive factors for the clinical course of bullous pemphigoid. .1 Am. Acad. Dermatol (1992) 26:585–589.
  • BYSTRYN JC, RAO D, NATOW S: Treatment of pemphigus with intravenous immunoglobulin. I Am. Acad. Dermatol (2002) 47:358–363.
  • KAZATCHKINE MD, KAVERI SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl. I Med. (2001) 345:747–755.
  • BHOL KC, DESAI A, KUMARI, COLON JE, AHMED AR: Pemphigus vulgaris: the role of IL-1 and 1L-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin. Immunol (2001) 100:172–180.
  • KUMARI S, BHOL KC, REHMAN F, FOSTER CS, AHMED AR: Interleukin 1 components in cicatricial pemphigoid: role in intravenous immunoglobulin therapy. Cytokine. (2001) 14:218.224.
  • VIARD L, VVEHRLI P, BULLANI R et al: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 282:490–493.
  • LETKO E, BHOL KC, FOSTER CS, AHMED AR: Influence of intravenous immunoglobulin therapy on serum levels of anti-B4 antibodies in ocular cicatricial pemphigoid. Carr: Eye Res. (2000) 21:646–654.
  • SAMI N, ALI S, BHOL KC, AHMED AR: Influence of IVIg therapy on autoantibody titers to BP Agl and BP Ag2 in patients with bullous pemphigoid. JEur Acad Dermatol (2003) 17:641–645.
  • SAMI N, BHOL KC, AHMED AR: Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin. Immunol (2002) 105(2):192–198
  • SAMI N, BHOL KC, AHMED AR: Influence of IVIg therapy on autoantibody titers to desmoglein 1 and 3 in patients with pemphigus vulgaris. Eur. I Immunol (2003) 13:377–381.
  • AHMED AR, DAHL M: For the Consensus Development Group. Consensus statement on the use of intravenous therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol (2003) 139(8):1051–1059.
  • •Valuable manuscript that carefully describes all aspects of the therapy.
  • JOLLES S, HUGHES J, WHITTAKER S: Dermatological uses of high-dose intravenous immunoglobulin. Arch. Dermatol (1998) 134:80–86.
  • MOBINI N, SARELA A, AHMED AR: Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann. Allergy Asthma Immunol (1995) 74:199–128.
  • RUTTER A, LUGER TA: High-dose intravenous immunoglobulins: a promising approach to treat severe immune-mediated and autoimmune diseases of the skin. I Am. Acad. Dermatol (2001) 44:1010–1024.
  • ELKAYAM 0, PARAN D, MILO R et al.: Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune diseases: a study of four cases. Ann. Rheum. Dis. (2000) 59:77–80.
  • GO RS, CALL TG: Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Clin. Proc. (2000) 75:83–85.
  • Appropriate use of human immunoglobulin in clinical practice: memorandum from an TUTS/WHO meeting. Bull. World Health Organ. (1982) 60:43–47.
  • HETHERINGTON SV, GIEBINK GS: Opsonic activity of immunoglobulin prepared for intravenous use. Lab. Clin. Med. (1984) 104:977–986.
  • SCHRODER DD, TANKERSLEY DL, LUNDBLAD JL: A new preparation of modified immune serum globulin (human) suitable for intravenous administration, II: functional characterization. Vox Sang. (1981) 40:383–394.
  • VAN FURTH R, LETJH PC, KLEIN F: Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use. Infect. Dis. (1984) 149:511–517.
  • VAN FURTH R, BRAAT AGP, PCJ, GARDI A: Opsonic activity and physiochemical characteristics of intravenous immunoglobulin preparations. Vox Sang. (1987) 53:70–75.
  • GIVNER LB: Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity and efficacy in animal models. Pediatrics (1990) 86:955–962.
  • SKVARIL F, ROTH-WICKY B, BARANDUM S: IgG subclasses in human g-globulin preparations for intravenous use and their reactivity with Staphylococcus protein A. Vox Sang. (1980) 38:147–155.
  • ROMER J, SPATH PJ, SKVARIL F, NYDEGGER UE: Characterization of various immunoglobulin preparations for intravenous application, II: complement activation and binding for Staphylococcus protein A. Vox Sang. (1982) 42:74–80.
  • DARLING AJ: Considerations in performing virus spiking experiments and process validation studies. Dev. Biol. Stand. (1993) 81:221–229.
  • Renal insufficiency and failure associated with immune globulin intravenous therapy. United States, 1985–1998. MMWR Morb. Mortal. Wkly Rep. (1999) 48:518–521.
  • SCHIFF RI, SEDLAK D, BUCKLEY RH: Rapid infusion of Sanoglobulin in patients with primary humoral immunodeficiency. J. Allergy Clin. Immunol (1991) 88:61–67.
  • VAN FURTH R, BRAAT AGP, PCJ, AND GARDI A: Opsonic activity and physiochemical characteristics of intravenous immunoglobulin preparations. Vox Sang. (1987) 53:70–75.

Websites

  • http://www.fda.gov/CBER/infosheets/ IGIV082702 Interim statement regarding IVIg. August 27, 2002. Accessed May 21, 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.